The Alzheimer’s Disease Research Center (ADRC) at Wake Forest School of Medicine brings together the latest technologies in neuroscience, neuropsychology, brain imaging and new treatments—all helping to find new ways to slow brain aging. The ADRC studies the role of metabolic and vascular risk factors in promoting the transition from normal aging to mild cognitive impairment, and then to Alzheimer’s or other forms of pathological brain aging such as vascular cognitive impairment (VCI). Our researchers aim to delay, prevent and ultimately cure Alzheimer’s disease and other dementia disorders.

Specifically, the Wake Forest ADRC provides infrastructure for translational, interdisciplinary research on the pathophysiology, prevention and treatment of Alzheimer’s disease and related disorders. Our ADRC focuses on the transition from normal aging to mild cognitive impairment and then to Alzheimer’s disease and other dementias, with emphasis on understanding the contribution of metabolic and vascular factors to these transitions. The ADRC is enrolling a diverse group of adults to facilitate the discovery of new biomarkers and promising targets for prevention and therapy. We also are using novel nonhuman primate models to promote pivotal mechanistic and translational research. Finally, we are educating new investigators in translational research practices, and educating health professionals, afflicted adults, their families and their communities about AD and strategies for reducing risk. The ADRC orchestrates these efforts through seven integrated Cores.

Research Cores